Print this page    •   Back to Web version of article

An Overview of Cobicistat (GS-9350)

October 25, 2010

Other Name(s): GS-9350
Drug Class: Opportunistic Infection and Other Drugs

Cobicistat, also known as GS-9350, is a type of medicine called a pharmacoenhancer or "boosting agent." This type of medicine works by raising blood levels of other drugs that are broken down by the same protein. Cobicistat, itself, does not have any antiviral activity.

Indications and Usage

Cobicistat is an investigational medicine that is not yet approved by the U.S. Food and Drug Administration (FDA) for use outside of clinical trials. It is being studied in combination with other drugs for the treatment of HIV infection.

Cobicistat is being studied in Phase III clinical trials as part of a single tablet fixed-dose combination regimen (also known as the "Quad" tablet). The "Quad" tablet contains the following four drugs: elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate.

In addition, cobicistat’s stand-alone role in boosting currently available HIV protease inhibitors is being studied in a clinical trial. This clinical trial involves studying cobicistat-boosted atazanavir, taken with emtricitabine/tenofovir disoproxil fumarate.

Cobicistat does not cure HIV infection and may not prevent you from developing HIV-related illnesses. Cobicistat does not prevent you from spreading HIV to other people.

Dosage Form/Administration

Cobicistat is currently used only in clinical trials. In these trials, cobicistat is taken by mouth. If you are currently taking cobicistat as part of a clinical trial, make sure to follow any specific instructions that have been given to you about participating in the trial. Unless your doctor or the research team tells you otherwise, please remember the following:


Individuals should tell a doctor about any medical problems before taking this medicine.

Possible Side Effects

If you are participating in a clinical trial or expanded access program, before taking cobicistat,

The following life threatening or serious side effects have been reported in clinical trials. Contact your doctor immediately if you experience:

Other nonserious side effects have also been reported in clinical trials:

Cobicistat may cause other side effects. Call your doctor if you have any unusual problems while taking this medication.

If you experience a serious side effect, you or your doctor may send a report to the FDA's MedWatch Adverse Event Reporting program online at or by phone 1-800-332-1088.

Drug Interactions

Certain medications or foods may interact with cobicistat.

Tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Your doctor may need to change the doses of your medications or monitor you more carefully for side effects.

Clinical Trials

Click here to search for trials that use Cobicistat.

Manufacturer Information

Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA 94404
Phone: (650) 574-3000
Fax: (650) 578-9264

This article was provided by AIDSinfo. You can find this article online by typing this address into your Web browser:

General Disclaimer: is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.